Clik here to view.
EBM Technologies Announces Industry Breakthrough with First FDA Cleared...
TAIPEI & CHICAGO EBM Technologies today announced that its vendor neutral, remote reading system Rad@ has been granted Class II FDA clearance for diagnostic reading of radiological images. This...
View ArticleClik here to view.
Terns Pharmaceuticalsがエリン・クワーク医師を最高医学責任者に任命したと発表
米カリフォルニア州サンマテオ & 上海 （ビジネスワイヤ） — NASHおよびがんの治療を目的とした分子標的経口低分子薬の創薬と開発に傾注する世界的なバイオ医薬品企業のTerns Pharmaceuticals...
View ArticleClik here to view.
US FDA Approves ONTRUZANT® (trastuzumab-dttb), Samsung Bioepis’ First...
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved ONTRUZANT® (trastuzumab-dttb), a biosimilar referencing HERCEPTIN® 1...
View ArticleClik here to view.
ファインデックス、視線分析型視野計GAPの薬事申請が受理
東京 （ビジネスワイヤ） — 株式会社ファインデックス（東証一部：3649 本社：東京 代表取締役：相原輝夫、以下ファインデックス）は、「視線分析型視野計ゲイズアナライジングペリメーターGAP（以下、GAP）」を開発し、2019年1月16日に医薬品医療機器総合機構（通称PMDA）への届け出が受理されました。...
View ArticleClik here to view.
Clik here to view.
Metabolon任命Michael Rasche为国际业务总裁
北卡罗来纳州罗利和德国波茨坦 (美国商业资讯)–代谢组学领域的全球领导者Metabolon今天宣布，Michael Rasche加盟公司担任国际业务总裁。Michael将向Metabolon总裁兼首席执行官Rohan Hastie汇报，并担任公司执行团队成员。他将负责Metabolon所有国际业务活动，重点关注客户与团队拓展。...
View ArticleClik here to view.
AVITA Medical Announces Nine RECELL® System Abstracts Accepted for...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that 26 abstracts highlighting the clinical and cost...
View ArticleClik here to view.
EpimAb Biotherapeutics Achieves Key Milestone with Lead Cancer Program EMB01
SHANGHAI EpimAb Biotherapeutics, an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, announced today completed recruitment of the first dose cohort in a...
View ArticleClik here to view.
Prenetics Group Expands Its Digital Health Solutions with Acquisition of...
LONDON Prenetics, a leading global genetics and digital health company, has today announced it has acquired Kelaa App, the core product of Soma Analytics and associated assets. Founded in Germany in...
View ArticleAvita Medical Second Quarter Fiscal 2019 Quarterly Cash Flow Report and...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced that it filed today with the ASX its Appendix 4C – Quarterly...
View ArticleClik here to view.
Repare Therapeutics Announces a Strategic Partnership Agreement With ONO...
MONTREAL & CAMBRIDGE, Mass. Repare Therapeutics, Inc., a privately held precision oncology company pioneering synthetic lethality to develop novel therapeutics that target specific...
View ArticleClik here to view.
武田薬品：2018年度第3四半期（4-12月期）の連結業績について
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社 (東証:4502)(NYSE:TAK)： 実質的な売上収益は＋4.8％、医療用医薬品の成長が牽引し、すべての地域で増収 実質ベースの売上収益の成長率は、タケダの成長ドライバー（消化器系疾患領域、オンコロジー、ニューロサイエンス、新興国事業）の＋10.5％の継続的な伸長により、対前年同期＋4.8％...
View ArticleClik here to view.
Takeda Reports Third Quarter FY2018 Results
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK): Underlying Revenue +4.8% year-to-date with growth of prescription drug portfolio in all regions Solid Underlying Revenue...
View ArticleClik here to view.
Rockwood Equity Partners and SYNEO Team Partner on Management Buyout
WEST PALM BEACH, Fla. Rockwood Equity Partners, a lower middle market private investment firm, announced today that it has completed a management buyout of SYNEO, a provider of manufacturing...
View ArticleClik here to view.
Samsung Bioepis and C-Bridge Capital to Develop and Commercialize...
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced its expansion in mainland China through a licensing agreement with C-Bridge Capital. The agreement covers multiple biosimilar candidates from...
View ArticleClik here to view.
European Commission Approves ADCETRIS® (brentuximab vedotin) with AVD, the...
CAMBRIDGE, Mass. and OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) extended the current marketing authorization of ADCETRIS...
View ArticleClik here to view.
Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved...
NEW YORK & TOKYO Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today results from the Phase 3 ARCHES trial in men...
View ArticleClik here to view.
武田公布2018财年第三季度业绩
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TOKYO:4502, NYSE:TAK)： 本年至今基础营收增长+4.8%，处方药产品组合在各个地区均有增长 基础营收稳步增长+4.8%，武田的增长引擎（胃肠药、肿瘤药、神经科药物和新兴市场）维持了强劲势头 ，增长+10.5%。 主要增长产品Entyvio...
View ArticleClik here to view.
H.I.G.Capital完成对Taconic Biosciences的收购
波士顿 –(美国商业资讯)–旗下管理着300亿美元股权资本的领先全球私募股权投资公司H.I.G.Capital (“H.I.G.”)欣然宣布，其附属公司之一已与Taconic Biosciences, Inc.（“Taconic”或“该公司”）管理团队合作支持该公司成长为制药、生物科技、合同研究组织(CRO)和学术研究行业领先的全球研究模型和服务提供商。...
View ArticleClik here to view.
キャピタルがタコニック・バイオサイエンシズの買収を完了
ボストン — （ビジネスワイヤ） — 運用資産300億ドルの世界的に有力なプライベート・エクイティ投資会社のHIGキャピタルは、当社投資先企業の1つがタコニック・バイオサイエンシズ（「タコニック」または「同社」）の経営陣と提携したことを発表します。製薬、バイオテクノロジー、CRO、学術研究機関に研究用のモデルとサービスを提供する世界一流企業としての同社の成長を支えることが目的です。...
View Article